Neoadjuvant anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: short-term results of an open-label, randomized, phase ii trial

HIGHLIGHTS

• who: Ying-Jian Wang et al. from the China Tianjin Medical Cancer China have published the Article: Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial, in the Journal: (JOURNAL)
• what: The authors evaluated the efficacy of neoadjuvant Anlotinib combined with nCT for patients with locally advanced ESCC by comparing it with nCRT alone. It was worth noting that patients who received neoadjuvant Anlotinib plus nCT in the study had less blood loss (52.4 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.